vs

Side-by-side financial comparison of PEDEVCO CORP (PED) and RxSight, Inc. (RXST). Click either name above to swap in a different company.

RxSight, Inc. is the larger business by last-quarter revenue ($32.6M vs $23.1M, roughly 1.4× PEDEVCO CORP). RxSight, Inc. runs the higher net margin — -28.1% vs -36.8%, a 8.8% gap on every dollar of revenue. On growth, PEDEVCO CORP posted the faster year-over-year revenue change (118.2% vs -18.9%). Over the past eight quarters, PEDEVCO CORP's revenue compounded faster (68.6% CAGR vs 5.1%).

PEDEVCO Corp is an independent energy company specializing in the acquisition, exploration, development, and production of oil and natural gas assets. It primarily holds and operates onshore resource properties across continental US basins, serving domestic wholesale, utility, and industrial energy customer segments.

RxSight, Inc. is a medical technology company focused on developing and commercializing innovative intraocular lens solutions for patients undergoing cataract and refractive lens exchange procedures. Its flagship Light Adjustable Lens allows post-surgery power adjustment via a dedicated light delivery device, serving global ophthalmology care markets to improve post-operative visual outcomes for patients.

PED vs RXST — Head-to-Head

Bigger by revenue
RXST
RXST
1.4× larger
RXST
$32.6M
$23.1M
PED
Growing faster (revenue YoY)
PED
PED
+137.2% gap
PED
118.2%
-18.9%
RXST
Higher net margin
RXST
RXST
8.8% more per $
RXST
-28.1%
-36.8%
PED
Faster 2-yr revenue CAGR
PED
PED
Annualised
PED
68.6%
5.1%
RXST

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PED
PED
RXST
RXST
Revenue
$23.1M
$32.6M
Net Profit
$-8.5M
$-9.2M
Gross Margin
77.5%
Operating Margin
-21.3%
-34.8%
Net Margin
-36.8%
-28.1%
Revenue YoY
118.2%
-18.9%
Net Profit YoY
-243.5%
-54.1%
EPS (diluted)
$-2.23
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PED
PED
RXST
RXST
Q4 25
$23.1M
$32.6M
Q3 25
$7.0M
$30.3M
Q2 25
$7.0M
$33.6M
Q1 25
$8.7M
$37.9M
Q4 24
$10.6M
$40.2M
Q3 24
$9.1M
$35.3M
Q2 24
$11.8M
$34.9M
Q1 24
$8.1M
$29.5M
Net Profit
PED
PED
RXST
RXST
Q4 25
$-8.5M
$-9.2M
Q3 25
$-325.0K
$-9.8M
Q2 25
$-1.7M
$-11.8M
Q1 25
$140.0K
$-8.2M
Q4 24
$5.9M
$-5.9M
Q3 24
$2.9M
$-6.3M
Q2 24
$2.7M
$-6.1M
Q1 24
$773.0K
$-9.1M
Gross Margin
PED
PED
RXST
RXST
Q4 25
77.5%
Q3 25
79.9%
Q2 25
74.9%
Q1 25
74.8%
Q4 24
71.6%
Q3 24
71.4%
Q2 24
69.5%
Q1 24
70.1%
Operating Margin
PED
PED
RXST
RXST
Q4 25
-21.3%
-34.8%
Q3 25
-12.0%
-40.1%
Q2 25
-32.2%
-41.6%
Q1 25
1.7%
-28.2%
Q4 24
-12.9%
-21.5%
Q3 24
31.3%
-26.1%
Q2 24
22.3%
-23.9%
Q1 24
7.6%
-36.2%
Net Margin
PED
PED
RXST
RXST
Q4 25
-36.8%
-28.1%
Q3 25
-4.7%
-32.4%
Q2 25
-24.0%
-35.0%
Q1 25
1.6%
-21.6%
Q4 24
56.0%
-14.8%
Q3 24
32.2%
-17.9%
Q2 24
22.7%
-17.4%
Q1 24
9.5%
-30.8%
EPS (diluted)
PED
PED
RXST
RXST
Q4 25
$-2.23
$-0.22
Q3 25
$0.00
$-0.24
Q2 25
$-0.02
$-0.29
Q1 25
$0.00
$-0.20
Q4 24
$2.69
$-0.14
Q3 24
$0.03
$-0.16
Q2 24
$0.03
$-0.16
Q1 24
$0.01
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PED
PED
RXST
RXST
Cash + ST InvestmentsLiquidity on hand
$3.2M
$228.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$207.4M
$275.7M
Total Assets
$375.9M
$311.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PED
PED
RXST
RXST
Q4 25
$3.2M
$228.1M
Q3 25
$10.9M
$227.5M
Q2 25
$8.5M
$227.5M
Q1 25
$10.4M
$229.3M
Q4 24
$4.0M
$237.2M
Q3 24
$4.6M
$237.1M
Q2 24
$6.1M
$233.3M
Q1 24
$13.3M
$125.4M
Stockholders' Equity
PED
PED
RXST
RXST
Q4 25
$207.4M
$275.7M
Q3 25
$115.4M
$276.0M
Q2 25
$115.2M
$278.0M
Q1 25
$116.2M
$279.3M
Q4 24
$115.6M
$281.2M
Q3 24
$106.5M
$277.3M
Q2 24
$103.2M
$275.2M
Q1 24
$100.0M
$163.9M
Total Assets
PED
PED
RXST
RXST
Q4 25
$375.9M
$311.8M
Q3 25
$135.9M
$308.5M
Q2 25
$136.8M
$309.0M
Q1 25
$145.6M
$313.0M
Q4 24
$128.3M
$318.6M
Q3 24
$114.3M
$310.5M
Q2 24
$111.0M
$305.5M
Q1 24
$118.3M
$183.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PED
PED
RXST
RXST
Operating Cash FlowLast quarter
$-2.1M
$-1.1M
Free Cash FlowOCF − Capex
$-2.3M
FCF MarginFCF / Revenue
-6.9%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-19.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PED
PED
RXST
RXST
Q4 25
$-2.1M
$-1.1M
Q3 25
$7.4M
$-1.2M
Q2 25
$-420.0K
$-4.4M
Q1 25
$5.9M
$-8.8M
Q4 24
$4.2M
$-4.3M
Q3 24
$8.3M
$650.0K
Q2 24
$4.6M
$-4.0M
Q1 24
$-4.3M
$-9.3M
Free Cash Flow
PED
PED
RXST
RXST
Q4 25
$-2.3M
Q3 25
$-1.8M
Q2 25
$-5.9M
Q1 25
$-9.4M
Q4 24
$-5.1M
Q3 24
$-453.0K
Q2 24
$-5.5M
Q1 24
$-11.3M
FCF Margin
PED
PED
RXST
RXST
Q4 25
-6.9%
Q3 25
-5.8%
Q2 25
-17.6%
Q1 25
-24.8%
Q4 24
-12.7%
Q3 24
-1.3%
Q2 24
-15.9%
Q1 24
-38.2%
Capex Intensity
PED
PED
RXST
RXST
Q4 25
3.5%
Q3 25
1.9%
Q2 25
4.6%
Q1 25
1.5%
Q4 24
2.1%
Q3 24
3.1%
Q2 24
4.4%
Q1 24
6.7%
Cash Conversion
PED
PED
RXST
RXST
Q4 25
Q3 25
Q2 25
Q1 25
42.34×
Q4 24
0.71×
Q3 24
2.83×
Q2 24
1.71×
Q1 24
-5.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PED
PED

Segment breakdown not available.

RXST
RXST

Rxlal$28.2M86%
LDD$3.0M9%
Service Warranty Service Contracts And Accessories$1.5M4%

Related Comparisons